Fertility decline & demographic stagnation

The lever most likely to move fast is not policy, it is cost. Fertility decline has at least four causes (housing, childcare, biological fertility, culture), and three of the four move on generational timescales even under aggressive policy. The fourth, the direct cost and accessibility of fertility treatment for people who want children and cannot conceive easily, is a solvable engineering and market problem today, and it is the one this whitepaper focuses the dollar math on, because it is the one buildable now. Why now: IVF technology itself has not changed all that dramatically in the price-relevant sense, and that is precisely the opportunity. A single IVF cycle costs $12,000 to $15,000 in the US (Fortune Business Insights, CARE Fertility 2026 cost analysis), largely because the process is still embryologist-labor-intensive and clinic-capacity-constrained, not because the underlying reagents or lab time are intrinsically that expensive. Lab automation, AI-assisted embryo selection and grading, and clinic-capacity software have started to appear but have not yet been applied aggressively to IVF cost structure the way, for example, automation compressed the cost of DNA sequencing by several orders of magnitude over two decades. That is the buildable unlock: a materially cheaper IVF and fertility-preservation pipeline through lab automation and software, not a new biological breakthrough. The dollar value, worked from real numbers: The World Health Organization estimates that infertility affects around 48 million couples worldwide (WHO, cited across IVF market research including Fortune Business Insights and CARE Fertility's 2026 analysis). Not all 48 million will ever seek treatment, cost and access are exactly why not, but that is the real global population of people who need this. At an average cost of roughly $13,500 per cycle (midpoint of the commonly cited $12,000 to $15,000 range), even a modest fraction seeking treatment produces a large number: if a quarter of the 48 million couples, 12 million, sought and paid for one full cycle, that is a $162 billion market. The current global IVF market is valued at roughly $31 billion in 2026 (Fortune Business Insights), which means something close to $130 billion of latent, real demand exists but goes unmet purely on cost and clinic-capacity grounds. That gap, not the $31 billion current market, is the honest addressable opportunity: it is demand that already exists (people who want children and cannot conceive without help) constrained by a solvable cost problem, not demand that has to be created. There is a second, cheaper wedge inside the same number: fertility preservation (egg and sperm freezing) as insurance against the biological-fertility-decline driver, currently priced around $10,000 to $15,000 for the freezing procedure plus $500-plus a year in storage, which is itself a smaller and more elastic version of the same cost problem, and a plausible first product for a company attacking the space before it takes on full IVF cost structure. What would actually have to get built: an IVF and fertility-preservation provider that treats lab automation, embryologist-augmenting AI tooling, and clinic throughput as the core product, the way a modern surgical-robotics company treats procedure cost as the product, with a target of cutting the effective cost per cycle by half or more through capacity and automation gains rather than by cutting quality. A 50 percent cost reduction alone, from $13,500 to roughly $6,750 per cycle, would by itself unlock a meaningfully larger share of the underserved 36 million couples who are not currently in the treated 12 million. This is squarely inside this project's "unambiguously good" filter: nobody wants fewer people to have the children they want, the demand is not manufactured, and the constraint is a fixable cost and capacity problem rather than an unsolved biological one. It is also, per this problem's own severity estimate, sitting under a much larger and more diffuse cost: below-replacement fertility carries a real, if hard to price precisely, drag on long-run GDP through demographic contraction, which dwarfs the $162 billion direct-treatment figure but is much harder to attack directly. The IVF-cost wedge is the tractable piece of a much larger problem. Conjecture, open to refutation: the 25 percent treatment-seeking assumption behind the $162 billion figure is a rough estimate, not a survey finding, chosen as a plausible middle case between the current tiny treated share and full addressable demand. The real number could be meaningfully higher or lower depending on how much of the 48 million WHO figure reflects couples who, even at zero cost, would not seek treatment.